|
18 Oct 2019 |
Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
|
|
18 Oct 2019 |
Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
|
|
18 Oct 2019 |
CHMP Grants Positive Opinion for Expanded Use of Janssen’s Darzalex (daratumumab) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
|
|
18 Oct 2019 |
ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma
|
|
18 Oct 2019 |
EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
|
|
17 Oct 2019 |
Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease
|
|
17 Oct 2019 |
[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
|
|
17 Oct 2019 |
NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar Candidate in Phase I Clinical Trial
|
|
17 Oct 2019 |
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
|
|
17 Oct 2019 |
Ichnos Sciences Launches as New, Independent, Leading-Edge Biotech Dedicated to Outpacing Disease
|
|
16 Oct 2019 |
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
|
|
16 Oct 2019 |
Amphivena Initiates Solid Tumor Clinical Trial
|
|
16 Oct 2019 |
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
|
|
15 Oct 2019 |
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
|
|
15 Oct 2019 |
Affimed Reports Progress on Key Clinical Development Programs
|
|
15 Oct 2019 |
Immutep reports positive final efficacy data from TACTI-mel trial in melanoma
|
|
14 Oct 2019 |
I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
|
|
14 Oct 2019 |
Femtogenix Presents Efficacy and Toxicity Data on Antibody Drug Conjugates Containing New Generation of DNA-binding Therapeutic Payloads
|
|
14 Oct 2019 |
Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
|
|
11 Oct 2019 |
Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
|
|
10 Oct 2019 |
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
|
|
10 Oct 2019 |
Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer
|
|
10 Oct 2019 |
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
|
|
09 Oct 2019 |
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
|
|
09 Oct 2019 |
Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma
|
